RefCheck Maintenance Notice

On Monday, December 3, 2018, from 16:00-18:00 EST, RefCheck will be undergoing maintenance. RefCheck is the process where, during copyediting, all references are extracted from the manuscript file, parsed, matched against various databases (eg, PubMed and CrossRef), and automatically corrected. For more information on RefCheck, please visit our Knowledge Base.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 17.11.16 in Vol 5, No 4 (2016): Oct-Dec

This paper is in the following e-collection/theme issue:

Works citing "Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya"

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.6617):

(note that this is only a small subset of citations)

  1. Smit MR, Ochomo EO, Waterhouse D, Kwambai TK, Abong'o BO, Bousema T, Bayoh NM, Gimnig JE, Samuels AM, Desai MR, Phillips-Howard PA, Kariuki SK, Wang D, ter Kuile FO, Ward SA, Aljayyoussi G. Pharmacokinetics-Pharmacodynamics of High-Dose Ivermectin with Dihydroartemisinin-Piperaquine on Mosquitocidal Activity and QT-Prolongation (IVERMAL). Clinical Pharmacology & Therapeutics 2018;
    CrossRef
  2. Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong'o BO, Chen T, Bousema T, Slater HC, Waterhouse D, Bayoh NM, Gimnig JE, Samuels AM, Desai MR, Phillips-Howard PA, Kariuki SK, Wang D, Ward SA, ter Kuile FO. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases 2018;18(6):615
    CrossRef
  3. Muñoz J, Ballester MR, Antonijoan RM, Gich I, Rodríguez M, Colli E, Gold S, Krolewiecki AJ, Prichard RK. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLOS Neglected Tropical Diseases 2018;12(1):e0006020
    CrossRef
  4. Chaccour CJ, Hammann F, Alustiza M, Castejon S, Tarimo BB, Abizanda G, Irigoyen Barrio , Martí Soler H, Moncada R, Bilbao JI, Aldaz A, Maia M, Del Pozo JL. Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae . Scientific Reports 2017;7(1)
    CrossRef
  5. Kobylinski KC, Ubalee R, Ponlawat A, Nitatsukprasert C, Phasomkulsolsil S, Wattanakul T, Tarning J, Na-Bangchang K, McCardle PW, Davidson SA, Richardson JH. Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles . Malaria Journal 2017;16(1)
    CrossRef
  6. Kobylinski KC, Escobedo-Vargas KS, López-Sifuentes VM, Durand S, Smith ES, Baldeviano GC, Gerbasi RV, Ballard S, Stoops CA, Vásquez GM. Ivermectin susceptibility, sporontocidal effect, and inhibition of time to re-feed in the Amazonian malaria vector Anopheles darlingi . Malaria Journal 2017;16(1)
    CrossRef
  7. Chaccour C, Hammann F, Rabinovich NR. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malaria Journal 2017;16(1)
    CrossRef

According to Crossref, the following books are citing this article (DOI 10.2196/resprot.6617)

:
  1. D’Alessandro U. Towards Malaria Elimination - A Leap Forward. 2018. Chapter 1
    CrossRef